Structured evidence table for Selenium Blood Pressure Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Selenium Blood Pressure Meta-Analysis | The analysis calculated summary relative risks (RR) and 95% confidence intervals (95% CI) for the risk of hypertension by comparing the highest versus lowest levels of circulating selenium and using random-effects models. | 1 | Khodadadi H (2025) | Dose-response association between circulating selenium and blood pressure: a systematic review and meta-analysis. |
| Selenium Blood Pressure Meta-Analysis | The highest versus lowest level of circulating selenium was not significantly related to risk of hypertension (RR:1.15; 95% CI: 0.99-1.33). | 1 | Khodadadi H (2025) | Dose-response association between circulating selenium and blood pressure: a systematic review and meta-analysis. |
| Selenium Blood Pressure Meta-Analysis | lowest circulating selenium was associated with a 36% higher risk of hypertension in women (95% CI: 1.03-1.81). | 1 | Khodadadi H (2025) | Dose-response association between circulating selenium and blood pressure: a systematic review and meta-analysis. |
| Selenium Blood Pressure Meta-Analysis | Aim and scope Hypertension is considered a global health issue due to its growing prevalence. | 1 | Khodadadi H (2025) | Dose-response association between circulating selenium and blood pressure: a systematic review and meta-analysis. |
| Selenium Blood Pressure Meta-Analysis | Despite major advancements in pharmacotherapies and interventional cardiology, substantial residual risk persists among patients with established disease (). | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
| Selenium Blood Pressure Meta-Analysis | Additionally, many nutraceuticals are perceived to possess favorable safety and tolerability profiles compared to conventional medications, making them attractive for long-term risk reduction (). | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
| Selenium Blood Pressure Meta-Analysis | Banach et al., 2018 Cicero et al., 2017 Sesso et al., 2008 However, the field is marked by heterogeneous and sometimes contradictory evidence. | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
| Selenium Blood Pressure Meta-Analysis | Roth et al., 2020 Ganda et al., 2018 Visseren et al., 2021 Cardiovascular disease (CVD) is the leading cause of mortality worldwide, accounting for nearly one-third of global deaths each year (). | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
Source documents